Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand.

Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand.

RV144 was a community-based HIV vaccine efficacy trial conducted in HIV-uninfected adults in Thailand, where dengue virus continues to cause a large number of infections every year. We attempted to document the accuracy of clinically diagnosed dengue episodes reported as serious adverse events (SAEs...

Full description

Bibliographic Details
Main Authors:	Punnee Pitisuttithum, Supachai Rerks-Ngarm, Donald Stablein, Peter Dawson, Sorachai Nitayaphan, Jaranit Kaewkungwal, Nelson L Michael, Jerome H Kim, Merlin L Robb, Robert J O'Connell, In-Kyu Yoon, Stefan Fernandez, Jean-Louis Excler
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4444125?pdf=render

Similar Items

Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees.
by: Ickwon Choi, et al.
Published: (2015-04-01)

Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees
by: Choi, Ickwon, et al.
Published: (2015)

IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees
by: Stephanie Fischinger, et al.
Published: (2020-11-01)

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee
by: Nathan I. Nicely, et al.
Published: (2015-07-01)

V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.
by: Lautaro G Perez, et al.
Published: (2017-01-01)

CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.
by: Kalpana Dommaraju, et al.
Published: (2014-01-01)

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
by: Siriwat Akapirat, et al.
Published: (2018-01-01)

Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.
by: Paul T Edlefsen, et al.
Published: (2015-02-01)

RV144 HIV-1 vaccination impacts post-infection antibody responses.
by: Thembi Mdluli, et al.
Published: (2020-12-01)

Correction: RV144 HIV-1 vaccination impacts post-infection antibody responses.
by: Thembi Mdluli, et al.
Published: (2021-03-01)

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine
by: Slim Fourati, et al.
Published: (2019-02-01)

An HIV Vaccine for South-East Asia—Opportunities and Challenges
by: Jerome H. Kim, et al.
Published: (2013-08-01)

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
by: Raphael Gottardo, et al.
Published: (2013-01-01)

A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection
by: Yufei Wang, et al.
Published: (2017-04-01)

V1/V2-directed antibodies elicited in RV144 vaccinees bind to a structurally polymorphic site
by: McLellan JS, et al.
Published: (2012-09-01)

Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand.
by: Punnee Pitisuttithum, et al.
Published: (2011-01-01)

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.
by: David Easterhoff, et al.
Published: (2017-02-01)

P14-05. Recruitment, retention and participation impact events among women participating in phase III community trial in Thailand
by: Benenson MW, et al.
Published: (2009-10-01)

Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.
by: Kristina K Peachman, et al.
Published: (2015-01-01)

Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E.
by: Silvia Ratto-Kim, et al.
Published: (2015-01-01)

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women.
by: Peter B Gilbert, et al.
Published: (2017-01-01)

Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses
by: Susan Zolla-Pazner, et al.
Published: (2014-11-01)

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
by: Francis D, et al.
Published: (2009-10-01)

T-cell based sieve analysis ties HLA A*02 to vaccine efficacy and IgA-C1 immune correlate in RV144 Thai trial
by: Hertz T, et al.
Published: (2012-09-01)

Extensive glycoform heterogeneity in the gp120 envelope proteins used in the RV144 trial
by: Yu B, et al.
Published: (2012-09-01)

Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection.
by: Sarah Auclair, et al.
Published: (2018-02-01)

Risk Factors for HIV sero-conversion in a high incidence cohort of men who have sex with men and transgender women in Bangkok, Thailand
by: Tanyaporn Wansom, et al.
Published: (2021-08-01)

Correction: Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial.
by: PLOS Computational Biology Staff
Published: (2016-01-01)

Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies.
by: Rachel C Doran, et al.
Published: (2018-01-01)

A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination
by: Melissa M. Lemke, et al.
Published: (2021-09-01)

Epidemiological profiles of recurrent malaria episodes in an endemic area along the Thailand-Myanmar border: a prospective cohort study
by: Saranath Lawpoolsri, et al.
Published: (2019-04-01)

A144
by: T. Khramova, et al.
Published: (2015-11-01)

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.
by: Susan Zolla-Pazner, et al.
Published: (2014-01-01)

Investigation of the Rv3065, Rv2942, Rv1258c, Rv1410c, and Rv2459 efflux pump genes expression among multidrug-resistant Mycobacterium tuberculosis clinical isolates
by: Fatemeh Shahi, et al.
Published: (2021-07-01)

Antibody responses to V2 loop are induced by CRF01_A E and not Clade B envelopes
by: Karasavvas N, et al.
Published: (2012-09-01)

Humoral Responses to Rv1733c, Rv0081, Rv1735c, and Rv1737c DosR Regulon-Encoded Proteins of Mycobacterium tuberculosis in Individuals with Latent Tuberculosis Infection
by: Simon G. Kimuda, et al.
Published: (2017-01-01)

Rv2031c of Mycobacterium tuberculosis: a master regulator of Rv2028-Rv2031 (HspX) operon
by: Khurram eMushtaq, et al.
Published: (2015-04-01)

spiritan_news_144

Using all-cause mortality to define severe RV dilation with RV/LV volume ratio
by: Stephan P. L. Altmayer, et al.
Published: (2018-05-01)

HLA-A*0201-restricted CTL epitopes in Rv0350 and Rv0351 of latent Mycobacterium tuberculosis
by: Y. Sun, et al.
Published: (2014-04-01)